Spots Global Cancer Trial Database for monoclonal antibodies
Every month we try and update this database with for monoclonal antibodies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | NCT05804032 | Multiple Myelom... | Isatuximab Isatuximab Lenalidomide Bortezomib Dexamethasone | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | NCT04753879 | Metastatic Panc... | Nab-paclitaxel Gemcitabine Cisplatin Irinotecan Capecitabine Pembrolizumab Olaparib | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT02941601 | Locally Advance... Metastatic Squa... | Necitumumab Gemcitabine Carboplatin | 18 Years - | Eli Lilly and Company | |
| Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia | NCT01013961 | Chronic Lymphoc... | alemtuzumab rituximab | 65 Years - | Eastern Cooperative Oncology Group | |
| A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice | NCT06008691 | Non-Hodgkin Lym... | "novel" MAB (al... | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | NCT02941601 | Locally Advance... Metastatic Squa... | Necitumumab Gemcitabine Carboplatin | 18 Years - | Eli Lilly and Company | |
| Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) | NCT05771480 | Biliary Tract C... | Durvalumab Gemcitabine mon... Gemcitabine + c... Gemcitabine + o... Gemcitabine + c... Gemcitabine + c... Gemcitabine + S... Gemcitabine + c... | 18 Years - 130 Years | AstraZeneca | |
| Preoperative Panitumumab and Radiotherapy in Rectal Cancer | NCT00973193 | Rectal Cancer | panitumumab | 18 Years - | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | |
| This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | NCT03573544 | Metastatic Soli... Locally Advance... | OBI-888 OBI-888 Globo H IHC Ass... | 18 Years - | OBI Pharma, Inc | |
| Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) | NCT00923169 | Renal Cell Carc... | Anti-Transformi... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors. | NCT03573544 | Metastatic Soli... Locally Advance... | OBI-888 OBI-888 Globo H IHC Ass... | 18 Years - | OBI Pharma, Inc | |
| Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer | NCT02254941 | Metastatic Colo... | Chemotherapy Chemotherapy pl... | 18 Years - | Grupo Espanol Multidisciplinario del Cancer Digestivo | |
| Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) | NCT05771480 | Biliary Tract C... | Durvalumab Gemcitabine mon... Gemcitabine + c... Gemcitabine + o... Gemcitabine + c... Gemcitabine + c... Gemcitabine + S... Gemcitabine + c... | 18 Years - 130 Years | AstraZeneca | |
| Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma | NCT04506320 | Multiple Myelom... Stem Cell Trans... | 18 Years - | Gruppo Italiano Trapianto di Midollo Osseo | ||
| Part 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) | NCT00923169 | Renal Cell Carc... | Anti-Transformi... | 18 Years - | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
